Aristides Capital’s NeuroOne Medical Technologies NMTC Stock Holding History

Aristides Capital’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,133	Closed	-$71K	–	259
2021 Q4	$71K	Buy	+6,133	New	+$99.2K	0.03%	253

Other funds holding NMTC

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DWM

Drive Wealth Management Lehi, Utah $561M AUM 33.14% 1-Year Est. Return

Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Aristides Capital's NMTC Position: Q1 2022 in Review

Aristides Capital sold out of NeuroOne Medical Technologies (NMTC) in Q1 2022, closing a stake of 6,133 shares — an estimated $71K sold.

Aristides Capital first reported a position in NMTC in Q4 2021 and held it in 1 quarter. The position peaked at $71K in Q4 2021. 11 funds tracked by Wall St. Rank hold NMTC as of Q1 2022.

Aristides Capital reported no remaining NeuroOne Medical Technologies position as of Q1 2022 after selling out during the quarter.
Aristides Capital sold 6,133 NeuroOne Medical Technologies shares in Q1 2022, an estimated $71K.
Aristides Capital first reported a position in NeuroOne Medical Technologies in Q4 2021 and held it in 1 quarter.
Aristides Capital's NeuroOne Medical Technologies position peaked at $71K in Q4 2021.
11 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.